Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment [1]

European Psychiatry

Volumn 17, Issue 5, 2002, Pages 296-297

  Crocq, M A ^a   Leclercq, P ^b   Guillon, M S ^a   Bailey, P E ^a  

^a Centre Hospitalier de Rouffach   (France)

^b NONE   (France)

Author keywords

Augmentation therapy; Obsessive compulsive disorder; Olanzapine; Treatment unresponsive OCD

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFECT; FEMALE; HUMAN; LETTER; MALE; OBESITY; OBSESSION; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCORING SYSTEM; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PIRENZEPINE; QUESTIONNAIRES; RECURRENCE; RISPERIDONE;

EID: 0036747226     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(02)00673-9     Document Type: Letter

References (9)

1. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999;156:1834-5.
2. Marusic A, Farmer A. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder. Br J Psychiatry 2000;177:567.
3. Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-7.
4. Koran LM, Ringold MD, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000;61:514.
5. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of obsessive-compulsive disorder: a 12-week open trial. Psychiatry Res 2000;96:91-8.
6. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801.
7. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-8.
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
9. Pauwels PJ. 5-HT 1B/D receptor antagonists. Gen Pharmacol 1997;29:293-303.